Elevation Oncology amends bylaws for universal proxy rules and DGCL updates

Elevation Oncology, Inc.

Board approved amended bylaws effective March 3, 2023, to comply with SEC universal proxy rules.
New provisions require stockholders to certify compliance with Rule 14a-19 and provide evidence 5 business days before meeting.
Advance notice bylaws updated: additional disclosures, nominee interview requirement, and limit on nominees to board seats.
Changes align with recent Delaware law amendments on electronic notice, adjournment, and stockholder lists.
Added emergency bylaw provision for director quorum during crises; other ministerial and clarifying updates.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Elevation Oncology, Inc.: The Company amended and restated its bylaws to address universal proxy rules, update advance notice provisions, conform to recent DGCL amendments, and make other changes (effective 2023-03-03).

Change: bylaw amendment
Effective: 2023-03-03

Exact text from the filing

On March 3, 2023, in connection with the effectiveness of new U.S. Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “DGCL”) and a periodic review of the bylaws of Elevation Oncology, Inc. (the “Company”), the Company’s board of directors approved and adopted the Company’s amended and restated bylaws (the “Amended and Restated Bylaws”), which became immediately effective.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001558370-23-002780

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.